Ethyl hydrogen (4-{[4-({2-(diethylcarbamoyl)-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate → ethyl hydrogen (4-{[4-({6-[5-cyano-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)pyridin-3-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate

Participants

Reaction Steps

Prepared analogously to Compound 3A using diethyl (4-{[4-({6-[5-cyano-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)pyridin-3-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate (Compound 53B, 191 mg, 0.266 mmol) to afford 146 mg of the title compound (80%). 1H NMR (400 MHz, CD3OD) δ 9.15 (br. s., 1H), 8.47 (br. s., 1H), 8.33 (s, 1H), 7.89 (d, J=9.1 Hz, 1H), 7.61 (br. s., 1H), 7.12 (s, 1H), 6.95 (d, J=8.1 Hz, 1H), 4.49 (t, J=7.1 Hz, 2H), 3.83-3.93 (m, 5H), 3.60 (t, J=6.2 Hz, 2H), 2.99-3.07 (m, 2H), 2.97 (s, 3H), 2.16 (quin, J=6.5 Hz, 2H), 1.16 (t, J=7.1 Hz, 3H). MS (ESI): m/z=690.62 [M+H]+. UPLC: tR=1.26 min (UPLC-TOF: polar—2 min).

Provenance & Evidence